Clinical trials: Blinatumomab, active
Recurrent B Acute Lymphoblastic Leukemia
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement…
- Trial name
- NCT02101853
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab
- Where
- 186 sites in United States, Australia and 3 more
- Volunteers
- 669 people
- Sponsor
- National Cancer Institute (NCI)
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
The current Standard of Care (SoC) in younger patients with Ph+ ALL is Imatinib in combination with low-dose chemotherapy, change of TKI in case of persistent MRD above 10-3 after consolidation I and indication for stem cell…
- Trial name
- GMALL-EVOLVE (NCT06061094)
- Testing
- Imatinib, Ponatinib, Blinatumomab
- Where
- 85 sites in Germany
- Volunteers
- 220 people
- Sponsor
- Goethe University
Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
The investigators primary objective is to determine the safety and toxicity of incorporating blinatumomab into the post-allogeneic hematopoietic stem cell transplant (HSCT) maintenance setting for patients with CD19+-B-cell…
- Conditions
- Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia
- Trial name
- NCT03114865
- Testing
- Blinatumomab 9ug, Blinatumomab 28 ug, Blinatumomab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
This phase II trial studies how well low-intensity chemotherapy and ponatinib work in treating patients with Philadelphia chromosome-positive and/or BCR-ABL positive acute lymphoblastic leukemia that may have come back or is not…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03147612
- Testing
- Blinatumomab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Immunotherapy
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
This trial is a non-blinded, single-center, open-label, single-arm clinical study to evaluate a full-course immunotherapy regimen in patients with B-cell acute lymphoblastic leukemia (B-ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab Ozogamicin
- Trial name
- NCT06985485
- Testing
- Blinatumomab and Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Phase II Clinical Trial, Blinatumomab
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
- Conditions
- Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia
- Trial name
- NCT07178912
- Testing
- Blinatumomab, olverembatinib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Precursor B-Cell Lymphoblastic Leukemia
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults.
- Trial name
- NCT06554626
- Testing
- Dexamethasone, Blinatumomab, Venetoclax
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
- Trial name
- NCT06308588
- Testing
- Blinatumomab, Asciminib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia
This phase II trial compares the combination of inotuzumab ozogamicin and low intensity chemotherapy and blinatumomab to the usual chemotherapy with blinatumomab in treating patients with B-cell acute lymphoblastic leukemia or…
- Trial name
- NCT05303792
- Testing
- Cyclophosphamide, Vincristine, Dexamethasone
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 68 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed).
- Trial name
- NCT04546399
- Testing
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection
- Where
- 227 sites in United States, Australia and 2 more
- Volunteers
- 461 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Adult B-Cell
Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia
The GRAALL-QUEST study is a Phase 2 study nested in the GRAALL-2014/B study (NCT02617004). The GRAALL-QUEST study evaluates the safety and the efficacy of blinatumomab-containing consolidation and maintenance therapy in patients…
- Trial name
- GRAALL-QUEST (NCT03709719)
- Testing
- Blinatumomab Injection
- Where
- France
- Volunteers
- 95 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back…
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Trial name
- NCT03739814
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration
- Where
- 285 sites in United States, Puerto Rico
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
ALL, Adult, Philadelphia-Negative ALL
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as…
- Trial name
- BEAT-ALL-2024 (NCT06250959)
- Testing
- Blinatumomab Injection [Blincyto], Doxorubicin
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Chen Suning
Autoimmune Encephalitis (AE), Autoimmune Cerebellitis
Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
This is a multicenter, single-arm, continuous, prospective, interventional registry study designed to systematically evaluate the efficacy and safety of low-dose blinatumomab in patients with antibody-mediated refractory…
- Trial name
- NCT07686042
- Testing
- Blinatumomab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tiantan Hospital
B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma.
- Conditions
- B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia, B-Cell Lymphoblastic Leukemia, B-Cell Lymphoblastic Leukemia/Lymphoma
- Trial name
- BOOSTER (NCT07422337)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual…
- Trial name
- NCT06773936
- Testing
- Induction Phase, Re-Induction Phase, Post-Remission
- Where
- 16 sites in United States
- Volunteers
- 55 people
- Sponsor
- SWOG Cancer Research Network
ALL, Recurrent, Adult
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
This study is designed to determine the feasibility, safety, tolerability and maximum tolerated dose of Venetoclax in combination with Blinatumomab and to evaluate the response in patients treated with the combination of…
- Trial name
- NCT05182385
- Testing
- Blinatumomab, Venetoclax
- Where
- 17 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Goethe University
Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
This phase I/Ib trial tests the safety and side effects of asparaginase Erwinia chrysanthemi-recombinant-rywn (recombinant Erwinia asparaginase) and venetoclax in combination with blinatumomab and how well the combination works…
- Trial name
- NCT07133997
- Testing
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or…
- Trial name
- NCT06317662
- Testing
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 153 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab…
- Trial name
- NCT05645718
- Testing
- Cyclophosphamide, Vincristine, Blinatumomab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center